Bank of Nova Scotia Sells 1,971 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Bank of Nova Scotia decreased its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 30.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,512 shares of the biopharmaceutical company's stock after selling 1,971 shares during the period. Bank of Nova Scotia's holdings in Alnylam Pharmaceuticals were worth $1,062,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Larson Financial Group LLC grew its stake in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 73 shares in the last quarter. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter worth about $33,000. OFI Invest Asset Management bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Versant Capital Management Inc lifted its stake in Alnylam Pharmaceuticals by 77.6% in the 4th quarter. Versant Capital Management Inc now owns 190 shares of the biopharmaceutical company's stock valued at $45,000 after purchasing an additional 83 shares during the last quarter. Finally, IFP Advisors Inc grew its holdings in Alnylam Pharmaceuticals by 24.2% during the fourth quarter. IFP Advisors Inc now owns 241 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 47 shares during the period. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY traded up $4.06 during midday trading on Friday, reaching $234.56. 601,349 shares of the company were exchanged, compared to its average volume of 871,996. Alnylam Pharmaceuticals, Inc. has a one year low of $141.98 and a one year high of $304.39. The stock has a market cap of $30.51 billion, a P/E ratio of -108.09 and a beta of 0.30. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. The stock's 50-day moving average price is $249.14 and its 200-day moving average price is $257.07.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Alnylam Pharmaceuticals news, CMO Pushkal Garg sold 1,548 shares of the company's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.67, for a total value of $389,585.16. Following the sale, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,017,271.63. The trade was a 11.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Kevin Joseph Fitzgerald sold 1,440 shares of the firm's stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $251.56, for a total value of $362,246.40. Following the transaction, the executive vice president now owns 12,881 shares of the company's stock, valued at $3,240,344.36. This trade represents a 10.06 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 71,234 shares of company stock worth $19,958,097 in the last ninety days. Company insiders own 1.50% of the company's stock.

Analysts Set New Price Targets

A number of analysts have recently issued reports on the company. Bank of America raised their price objective on Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the company a "buy" rating in a research report on Friday, March 21st. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $284.00 to $268.00 and set an "equal weight" rating on the stock in a report on Friday, April 11th. Royal Bank of Canada upped their target price on Alnylam Pharmaceuticals from $310.00 to $330.00 and gave the company an "outperform" rating in a research report on Friday, March 21st. Wells Fargo & Company lifted their price target on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. Finally, Stifel Nicolaus upped their price objective on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a report on Monday, March 31st. One analyst has rated the stock with a sell rating, five have issued a hold rating and twenty-one have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $315.58.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.